Optogenetics Market To Generate Revenue worth $772.7 Million by 2030

The global optogenetics market is projected to generate USD 772.7 million revenue by 2030, advancing at a CAGR of 4.4% during 2024–2030. This will be a result of an increase in the incidence of psychiatric and neurological problems, such as depression and Parkinson’s disease. The World Health Organization estimates that depression affects 3.8% of the global population. Moreover, the market is growing due to the widening application area of optogenetics, such as post-trial considerations and diagnostics, especially the early detection of Parkinson’s disease.

Additionally, the growing pace of technological advancements in the field of optogenetics gives an enormous opportunity to researchers and scientists to enhance the outcomes for patients with diseases of the brain and the mind. Optogenetics is now expanding beyond the use of light-sensitive pumps and ion channels, to include other light-sensitive proteins, such as G-protein-modulating opsins. In cardiovascular research, for instance, both artificial and natural variants of these opsins are being used for the activation of cell signaling with high spatial and temporal precision. Despite these advances, cardiac optogenetics is still at the nascent stage for clinical translation. Therefore, the continuous R&D will create a lucrative opportunity for such technology in the future.

Neurosciences Holds Largest Revenue Share

By application, the neurosciences category accounts for the largest revenue share, of 40%, in 2023, and it is further expected to maintain its dominance during the forecast period. This is due to the major role of this technology in the diagnosis and treatment of neurodegenerative diseases, because the brain consists of neuron sets of various types, which organize themselves in complex 3D networks, thus creating a neural circuit to govern behavior. The patterns that encode the brain functions determine the functioning of these circuits. When the chemicals in the nervous system witness a compactness disbalance, psychiatric and neurological disorders occur. Stroke, Parkinson’s disease, and epilepsy are some of the highly prevalent neurological diseases that can be diagnosed with optogenetics techniques.

The behavior tracking category is expected to show the fastest growth over the forecast period. This is due to the growing adoption of optogenetics in behavior tracking, as optogenetic stimulation can be applied under time-specific conditions, such as for delivering a conditioned light stimulus, or when the subject’s behavior is of interest.

Globally, the APAC region is expected to register the fastest growth in the global optogenetics market during the forecast period. It is projected that the rising neurological disease burden in China and Japan and the large number of CROs in the region will drive the regional market growth. The rising count of clinical trials of this technology in the region is another significant factor for the growth of the market.

Moreover, the advancing regional infrastructure for research initiatives and the surging need to explore the field of neurosciences in more depth have led to a significant adoption of optogenetics among neurosurgeons and scientists for developing treatments for various diseases. Furthermore, the growth of the market is due to the existence of many players, constant augmentation in the intensity of research and development, improvements in the technical aspect, and enhancements in the healthcare infrastructure.

Some of the major players in the market are Laserglow Technologies, Coherent Corp., Thorlabs Inc., Gensight Biologics, Noldus Information Technology, Bruker Corporation, Scientifica Ltd., Elliot Scientific Ltd., and Shanghai Laser & Optics Century Co. Ltd.